Drug Profile

ORKA 001

Alternative Names: ORKA-001; ORKA-021; PR-035

Latest Information Update: 29 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Paragon Therapeutics
Developer Oruka Therapeutics; Paragon Therapeutics
Class Antibodies; Antipsoriatics; Monoclonal antibodies
Mechanism of Action Interleukin-23 subunit p19 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Plaque psoriasis

Most Recent Events

14 May 2025 Oruka Therapeutics plans a phase IIa proof-of-concept study for Psoriasis in the second half of 2025
06 Mar 2025 Pharmacokinetics and pharmacodynamic data from a preclinical trial in Plaque psoriasis released by Oruka Therapeutics
19 Dec 2024 Phase-I clinical trials in Plaque psoriasis (In volunteers) in New Zealand (SC) (NCT06698939)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com